An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Ongoing |
Inclacumab |
3 |
GBT2104-133 |
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi |
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises |
Ongoing |
Inclacumab |
3 |
GBT2104-132 |
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi |
Nucala Effectiveness Study (NEST) in Emerging Markets |
Completed |
Mepolizumab |
3 |
213475 |
King Fahad University Hospital (Al-Khobar) |
Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine use beyond 24 horse Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KASCH-NGHA |
Ongoing |
Dexmedetomidine |
3 |
RC20/160/R |
King Abdulaziz Medical City NG (Riyadh) |
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises |
Ongoing |
Inclacumab |
3 |
GBT2104-131 |
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia , Qatif Central Hospital |
The Efficacy of topical Povidone – Iodine rinses in the management of CoronaVirus disease 2019 (COVID-19) |
Ongoing |
POVIDONE IODINE |
2 |
E-20-5656 |
King Khalid University Hospital (Riyadh) |
Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial |
Ongoing |
Rituximab / Mycophenolate |
2 |
2020-99 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
A Prospective Phase II study utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients with Advanced Colorectal Cancer |
Ongoing |
PANITUMUMAB - cetuximab |
2 |
RC20/170/R |
King Abdulaziz Medical City NG (Riyadh) |
Deferoxamine management protocol in COVID-19 patients |
Ongoing |
Deferoxamine |
2 |
20082103 |
King Saud Medical City (Riyadh) |
A global multicenter,randomized,double-blind,placebo -controlled, adaptive designed phase Ⅲ clinical trial to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above |
Rejected |
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
3 |
CS-CTP-AD5NCOV-ⅢCo |
King Fahad Medical City (Riyadh) |